CytomX Therapeutics, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-08-06: Disclosure Non Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Rule10b51Arr Adopted; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
- 2026-08-06: Disclosure Non Rule10b51Arr Terminated; Period 2026-04-01..2026-06-30; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-08-06 10-Q | Non Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Rule10b51Arr Adopted | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-08-06 10-Q | Non Rule10b51Arr Terminated | 2026-04-01..2026-06-30 | No | |
| 2026-05-07 10-Q | Material Terms Of Trading Arrangement | 2026-01-01..2026-03-31 | Trading Arrangement On March 27, 2026 , Sean McCarthy , our Chief Executive Officer and Chairman , adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 200,000 shares of the Company’s common stock between January 4, 202… | |
| 2026-05-07 10-Q | Trading Arrangement Expiration Date | 2026-01-01..2026-03-31 | June 30, 2027 | |
| 2026-04-30 DEF 14A | Insider Trading Policies Proc Adopted | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Award Timing MNPI Disclosure | 2025-01-01..2025-12-31 | Equity Award Timing Policies and Practices We generally grant equity awards at regularly scheduled Board of Director or Compensation Committee meetings. We do not grant equity awards in anticipation of the release of material nonpublic information and we do not time the release of material nonpublic… | |
| 2026-04-30 DEF 14A | Award Timing Method | 2025-01-01..2025-12-31 | We generally grant equity awards at regularly scheduled Board of Director or Compensation Committee meetings. | |
| 2026-04-30 DEF 14A | Award Timing Predetermined | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Award Timing How MNPI Considered | 2025-01-01..2025-12-31 | We do not grant equity awards in anticipation of the release of material nonpublic information and we do not time the release of material nonpublic information for the purpose of affecting the value of executive compensation. In the event material nonpublic information becomes known to the Board of … | |
| 2026-04-30 DEF 14A | MNPI Disclosure Timed For Compensation Val | 2025-01-01..2025-12-31 | No | |
| 2026-04-30 DEF 14A | Award Timing MNPI Considered | 2025-01-01..2025-12-31 | Yes | |
| 2026-04-30 DEF 14A | Awards Close To MNPI Disclosure Table | 2025-01-01..2025-12-31 | The following table sets forth information regarding stock option grants made to the named executive officers during fiscal year 2025 within the period commencing four business days prior to or the one business day following our filing of a Form 8-K on February 3, 2025, that discloses non-public inf… | |
| 2026-04-30 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche1 | 2025-02-05 | Sean A. McCarthy, D. Phil |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche1 | 2025-02-05 | 800,000 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche1 | 2025-02-05 | 0.864 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche1 | 2025-02-05 | $691.20K |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche1 | 2025-02-05 | 0 |
| 2026-04-30 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche2 | 2025-02-05 | Sean A. McCarthy, D. Phil |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche2 | 2025-02-05 | 390,000 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche2 | 2025-02-05 | 0.864 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche2 | 2025-02-05 | $336.96K |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: SeanAMcCarthyDPhil; us-AwardType: Tranche2 | 2025-02-05 | 0 |
| 2026-04-30 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: ChrisOgden; us-AwardType: Tranche1 | 2025-02-05 | Chris Ogden |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: ChrisOgden; us-AwardType: Tranche1 | 2025-02-05 | 225,000 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: ChrisOgden; us-AwardType: Tranche1 | 2025-02-05 | 0.864 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: ChrisOgden; us-AwardType: Tranche1 | 2025-02-05 | $194.40K |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: ChrisOgden; us-AwardType: Tranche1 | 2025-02-05 | 0 |
| 2026-04-30 DEF 14A | Awards Close To MNPI Disclosure Individual Name | Individual: ChrisOgden; us-AwardType: Tranche2 | 2025-02-05 | Chris Ogden |
| 2026-04-30 DEF 14A | Award Undrlyg Securities | Individual: ChrisOgden; us-AwardType: Tranche2 | 2025-02-05 | 340,000 |
| 2026-04-30 DEF 14A | Award Exrc Price | Individual: ChrisOgden; us-AwardType: Tranche2 | 2025-02-05 | 0.864 |
| 2026-04-30 DEF 14A | Award Grant Date Fair Value | Individual: ChrisOgden; us-AwardType: Tranche2 | 2025-02-05 | $293.76K |
| 2026-04-30 DEF 14A | Undrlyg Security Mkt Price Chng Pct | Individual: ChrisOgden; us-AwardType: Tranche2 | 2025-02-05 | 0 |
| 2026-04-30 DEF 14A | Pay versus Performance Table | 2025-01-01..2025-12-31 | PAY VERSUS PERFORMANCE In accordance with rules adopted by the Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive compensation for our principal executive officer (“PEO”) and No… | |
| 2026-04-30 DEF 14A | Named Executive Officers Footnote | 2025-01-01..2025-12-31 | 1. Sean A. McCarthy, D. Phil. was our PEO for each year presented. The individuals comprising the Non-PEO NEOs for each year presented are listed below. 2023 2024 2025 Jeff Landau Chris Ogden Chris Ogden Marcia P. Belvin Wayne Chu Rachael Lester | |
| 2026-04-30 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2025-01-01..2025-12-31 | 3. Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the S… | |
| 2026-04-30 DEF 14A | Adjustment To PEO Compensation Footnote | 2025-01-01..2025-12-31 | 3. Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the Non-PEO NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the S… | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | -$3.31M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $9.21M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsInSummryCompstnTblForAplblYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | -$1.33M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTbl; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $2.39M |
| 2026-04-30 DEF 14A | Eqty Awrds Adjustment Footnote | 2025-01-01..2025-12-31 | The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables: Year Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Sean A. McCarthy, D. Phil. ($) Change in Fair Value from L… | |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $6.88M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $1.30M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $780.45K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $246.57K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: Peo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstd; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $1.95M |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrs; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $295.64K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $103.73K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $40.78K |
| 2026-04-30 DEF 14A | Adjustment To Compensation | AdjToComp: FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYr; ExecutiveCategory: NonPeoNeo | 2025-01-01..2025-12-31 | $0.00 |
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2025-01-01..2025-12-31 | Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”) The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and the Company’s cumulative … | |
| 2026-04-30 DEF 14A | Compensation Actually Paid Vs Net Income | 2025-01-01..2025-12-31 | Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs, and our Net Income during the three most recently completed… | |
| 2026-03-16 10-K | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-16 10-K | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-03-16 10-K | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-03-16 10-K | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |